Endothelin (ET) is a recently discovered 21-amino acid peptide that has potent physiologic and pathophysiologic effects that appear to be involved in the development of heart failure. These ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist ...

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

Pooled data from 30 trials, with 26,708 postmenopausal women followed for a mean duration of 4.5 years, indicate that hormone replacement does not increase total mortality. In the younger group ...

The green light is also a milestone for Novartis because it marks the first approval in its renal disease pipeline, which includes three therapies for IgAN – Fabhalta, oral endothelin A receptor ...

drug is an antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors, which are associated with progression of kidney disease. It's in late-stage development for IgA ...